PNC Financial Services Group
PETX

PNC Financial Services Group’s Aratana Therapeutics, Inc. PETX Stock Holding History

PNC Financial Services Group’s Portfolio PETX Stock Details PETX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-1,770
Closed -$8K – 4228
2019
Q2 		$8K Hold
1,770
– – ﹤0.01% 3646
2019
Q1 		$6K Hold
1,770
– – ﹤0.01% 3730
2018
Q4 		$12K Hold
1,770
– – ﹤0.01% 3508
2018
Q3 		$9K Hold
1,770
– – ﹤0.01% 3716
2018
Q2 		$7K Hold
1,770
– – ﹤0.01% 3785
2018
Q1 		$7K Buy
1,770
+6
+0.3% +$27 ﹤0.01% 3839
2017
Q4 		$8K Buy
1,764
+164
+10% +$1K ﹤0.01% 3770
2017
Q3 		$10K Hold
1,600
– – ﹤0.01% 3702
2017
Q2 		$12K Hold
1,600
– – ﹤0.01% 3538
2017
Q1 		$8K Hold
1,600
– – ﹤0.01% 3624
2016
Q4 		$11K Hold
1,600
– – ﹤0.01% 3461
2016
Q3 		$15K Hold
1,600
– – ﹤0.01% 3360
2016
Q2 		$10K Buy
1,600
+850
+113% +$5.47K ﹤0.01% 3575
2016
Q1 		$4K Buy
+750
New +$2.82K ﹤0.01% 3978

Other funds holding PETX

DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
ASN
Advisory Services Network Atlanta, Georgia $7.52B AUM 29.01% 1-Year Est. Return

PNC Financial Services Group's PETX Position: Q3 2019 in Review

PNC Financial Services Group sold out of Aratana Therapeutics, Inc. (PETX) in Q3 2019, closing a stake of 1,770 shares — an estimated $8K sold.

PNC Financial Services Group first reported a position in PETX in Q1 2016 and held it in 14 quarters. The position peaked at $15K in Q3 2016. 2 funds tracked by Wall St. Rank hold PETX as of Q3 2019.

  • PNC Financial Services Group reported no remaining Aratana Therapeutics, Inc. position as of Q3 2019 after selling out during the quarter.
  • PNC Financial Services Group sold 1,770 Aratana Therapeutics, Inc. shares in Q3 2019, an estimated $8K.
  • PNC Financial Services Group first reported a position in Aratana Therapeutics, Inc. in Q1 2016 and held it in 14 quarters.
  • PNC Financial Services Group's Aratana Therapeutics, Inc. position peaked at $15K in Q3 2016.
  • 2 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q3 2019.

Based on PNC Financial Services Group's 13F filing for Q3 2019, filed 8 Nov 2019.